Image from https://stabledifffusion.com/

SIBO (Small Intestine Bacterial Overgrowth) is fundamentally different than a pathogen in the gut; rather, it’s relatively benign bacteria, but in excessive amounts, and in the wrong place. But how does it get there—and why is it so notoriously difficult to get rid of it once it does?

The H2 “Food Chain”: The Producers

There are three types of SIBO (at least, that we know how to measure now), defined by the type of gas they overproduce: H2, CH4, and H2S. The bacteria that produce these all live in a symbiotic environment with one another—and they should be in the colon primarily, not the small intestine.

The H2 producers include species in the Bacteroidetes and Firmicutes phyla (more in the latter). These organisms break complex carbohydrates down into H2, CO2, and short chain fatty acids, the food for the colon.

H2 producers are “upstream” of the other two, as both CH4 and H2S producers consume H2. Their presence also supports the H2 producers, too, since excessive amounts of H2 gas (aside from the discomfort this might produce in the host) produces a feedback suppression mechanism, and actually decreases their own fermentation efficiency. This means less short chain fatty acids, among other things.

The H₂ consumers

The bacteria that consume H2 fall into three categories, only one of which isn’t associated with SIBO. These species compete with one another for the same food source. Which one wins depends upon the environment in the gut.

The one H2 sink not associated with a type of SIBO are the acetogens, primarily Blautia hydrogenotrophica. These consume H2 and CO2, and produce acetate (itself a useful short chain fatty acid) and water.

Methanogens are bacteria that consume H2 and CO2, and produce methane gas (CH4) and water. These are mostly the organism Methanobrevibacter smithii. CH4 isn’t toxic, but it does slow bowel transit, so those with CH4 SIBO tend toward constipation. Unfortunately, methanogens outcompete acetogens for hydrogen, if they’re present—they just have a higher affinity for it.

Sulfate-reducing bacteria (SRBs) are mostly the organism Desulfovibrio piger. These combine H2 with sulfate (SO4: the form often found in sulfur-containing foods), and reduce the latter to hydrogen sulfide gas (H2S) and water.

H2S is the most problematic product, in excess. Specifically, H2S can inhibit butyrate oxidation, preventing the colonocytes from using butyrate for repair, mucus production, and serotonin production to regulate motility. But only at high levels—in lower concentrations, H2S does not interfere with butyrate utilization.

H2S is also toxic to mitochondrial complex IV in the electron transport chain, leading to reduced ATP production—which will affect the mitochondria in the colon, since those are the cells that would be exposed.

It’s not all bad though: at lower levels, H2S has the exact opposite effect, acting a mitochondrial electron donor.

In other words, H2S is hormetic: the dose makes the poison.

SRBs also happen to outcompete the methanogens for H2—provided there’s enough sulfur around to feed them. Interestingly, the SRBs don’t outcompete with acetogens, though. (Probably good, so that we have a checks-and-balances situation going on in the gut, rather that one dominant kingpin.)

Long-Term SIBO Prevention: Treat the Terrain

Dr. Rudolph Virchow, considered the father of modern pathology, reportedly said, “If I could live my life over again, I would devote it to proving that germs seek their natural habitat – diseased tissue – rather than being the cause of dead tissue. In other words, mosquitoes seek the stagnant water, but do not cause the pool to become stagnant.”

While it might still be appropriate to treat SIBO with antimicrobials (herbal or antibiotic), we have to also keep in mind the environment that allowed them to thrive in the first place. Dr William Davis’s approach in “Super Gut” involves fermenting specific organisms, particularly lactobacillus reuteri, which effectively outcompetes other SIBO-associated organisms in the small intestine. Many of my patients have found this to be helpful.

Pro-motility agents are often utilized to try to prevent SIBO from crawling back up from the colon where they don’t belong, too. This is also helpful, if you can’t clearly identify or correct the reason for the slow-down in the first place (such as hypothyroidism, high dose progesterone which can slow bowel transit in sensitive individuals, a broad spectrum antibiotic, a GLP-1 or other pharmaceutical with bowel transit side effects, etc).

There might be a couple other useful pieces to the puzzle beyond these, as well.

Butyrate: A Potential Adjunct Therapy for SIBO

As mentioned above, particularly H2S SIBO can interfere with butyrate utilization by the colonocytes. Supplemented butyrate would likely be subject to similar interference, but high enough supplemented doses might nevertheless overcome this.

During CH4 SIBO treatment, there’s a risk for the population to switch to H2S dominance if we’re not careful—particularly if the SIBO test indicated relatively low H2 levels (suggesting the butyrate producers aren’t terribly robust). In this situation, adding butyrate during and shortly after treatment can also be helpful.

In pure H2 SIBO, butyrate might be less indicated, since the H2 producers also make butyrate. However, SIBO test results don’t tell us anything about whether the H2 producers are also abundant in the colon, where the butyrate would actually be useful. So if H2 SIBO is recurrent, it might be helpful in these cases, too.

Feed the Acetogens

Another potential strategy might be to try to increase the one H2 “sink” that doesn’t have the potential to lead to SIBO: the acetogens, which are only beneficial. Blautia (the dominant acetogen) doesn’t exist as a supplement yet, but especially after SIBO treatment, we can support it indirectly by feeding it.

Fortunately, of the H2 consumers, the acetogens are the only ones that don’t have to consume H2. If the H2 production is low, acetogens can switch to sugar fermentation (just as the H2 producers can) and simply carry on.

This is challenging during SIBO treatment, because the acetogens primarily consume fermentable carbs—the very thing feeding the SIBO. So timing is important: we can only add in those substrates in the recovery phase. Resistant starch combined with fiber works well for this.

An oligosaccharide from human milk called 2′-Fucosyllactose (2’-FL), which generally doesn’t cause as much gas and bloating as other carbs, also appears to increase Blautia in the presence of bifidobacillus. Bifidobacillus is necessary too, though, because Blautia actually eats a byproduct of bifidobacillus metabolism of 2’-FL. 2’-FL is commercially available.

Supporting bifidobacillus in general seems to be the best way to support the acetogen population at the moment, as the two are generally synergistic.

(If a stool culture shows low levels of the bifidobacillus genus, it’s important not just to supplement with it, but to identify why and address that at the same time—there’s usually an environmental toxin poisoning the good bacteria that will need to be addressed. Glyphosate is one I see commonly, though there are other possibilities too.)

The Upshot

If SIBO (any type) tends to recur, it’s usually because the populations are shuffling from one type to another, filling in a vacancy in the local ecosystem. The question is always why.